BiotechTube
Home/Pipeline/SPX-303

SPX-303

Oncology (unspecified)

Phase 1Active

Key Facts

Indication
Oncology (unspecified)
Phase
Phase 1
Status
Active
Company
SparX Biopharmaceutical

About SparX Biopharmaceutical

SparX Biopharmaceutical is a private, clinical-stage biotech pioneering next-generation antibody therapies for oncology. The company has built an integrated platform for antibody discovery and development, featuring proprietary technologies like SAILING™ for antibody discovery and SYNMAB™ for multispecifics, and has advanced its lead bispecific antibody, SPX-303, into Phase 1 trials. With a strategic research agreement with Mitsubishi Tanabe Pharma America and internal cGMP manufacturing capabilities, SparX is positioned to develop novel therapies that stimulate both innate and adaptive immunity, though it faces significant risks common to early-stage drug development.

View full company profile

Therapeutic Areas

Oncology

Other Oncology (unspecified) Drugs

DrugCompanyPhase
Oncology Vaccine ProgramCHAIN BiotechPre-clinical
ARX305NovoCodex BiopharmaceuticalsPhase 1
ARX788NovoCodex BiopharmaceuticalsPhase 1
Cancer Immunotherapy NanotherapeuticFlashpoint TherapeuticsPhase 1
GRWD5769Greywolf TherapeuticsPhase 1/2
Platform-derived Program(s)Immuto ScientificDiscovery/Pre-clinical
MBT Oncology ProgramIonic PharmaceuticalsPre-clinical
ISB 2301Ichnos Glenmark InnovationPreclinical
GRC 65327Ichnos Glenmark InnovationPreclinical
Platform-Derived PipelinePhinomicsDiscovery/Pre-clinical
Lead Small-Molecule InhibitorEris BiotechPre-clinical
Orotecan™Edison OncologyPhase 1/2a